CANCER THERAPY

Neoadjuvant immune-checkpoint blockade in resectable colon cancer

Neoadjuvant checkpoint blockade achieves deep or complete pathologic responses in patients with mismatch-repair-deficient and mismatch-repair-proficient early colon cancer.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Neoadjuvant CTLA-4–PD-1 blockade in colon cancer.

References

  1. 1.

    Le, D. T. et al. N. Engl. J. Med. 372, 2509–2520 (2015).

    CAS  Article  Google Scholar 

  2. 2.

    Chalabi, M. et al. Nat. Med. https://doi.org/10.1038/s41591-020-0805-8 (2020).

  3. 3.

    Wei, S. C., Duffy, C. R. & Allison, J. P. Cancer Discov. 8, 1069–1086 (2018).

    Article  Google Scholar 

  4. 4.

    Tumeh, P. C. et al. Nature 515, 568–571 (2014).

    CAS  Article  Google Scholar 

  5. 5.

    Thommen, D. S. et al. Nat. Med. 24, 994–1004 (2018).

    CAS  Article  Google Scholar 

  6. 6.

    Fairfax, B. P. et al. Nat. Med. 26, 193–199 (2020).

    CAS  Article  Google Scholar 

  7. 7.

    Yost, K. E. et al. Nat. Med. 25, 1251–1259 (2019).

    CAS  Article  Google Scholar 

  8. 8.

    Siddiqui, I. et al. Immunity 50, 195–211.e10 (2019).

    CAS  Article  Google Scholar 

  9. 9.

    Łuksza, M. et al. Nature 551, 517–520 (2017).

    Article  Google Scholar 

  10. 10.

    Liu, J. et al. Cancer Discov. 6, 1382–1399 (2016).

    CAS  Article  Google Scholar 

  11. 11.

    Pai, C. S. et al. Immunity 50, 477–492.e8 (2019).

    CAS  Article  Google Scholar 

  12. 12.

    Angelova, M. et al. Cell 175, 751–765.e16 (2018).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to George Coukos.

Ethics declarations

Competing interests

G.C. has received grants or research support from or is co-investigator in clinical trials by BMS, Celgene, Boehringer Ingelheim, Roche, Iovance and Kite, and has received honoraria for consultations or presentations by Roche, Genentech, BMS, AstraZeneca, Sanofi-Aventis, Nextcure and GeneosTx.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Coukos, G. Neoadjuvant immune-checkpoint blockade in resectable colon cancer. Nat Med 26, 473–474 (2020). https://doi.org/10.1038/s41591-020-0826-3

Download citation